Vident Investment Advisory, LLC Igm Biosciences, Inc. Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$13.74 - $25.76 $19,304 - $36,192	-1,405 Reduced 3.56%	38,078 $523,000
Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $73,016 - $122,970	-4,726 Reduced 10.69%	39,483 $671,000
Q3 2022 Nov 14, 2022	SELL	$15.42 - $27.01 $73,044 - $127,946	-4,737 Reduced 9.68%	44,209 $1.01 Million
Q2 2022 Aug 15, 2022	BUY	$13.27 - $25.5 $649,513 - $1.25 Million	48,946 New	48,946 $882,000
Q4 2021 Feb 14, 2022	SELL	$27.59 - $66.39 $430,486 - $1.04 Million	-15,603 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$65.76 - $90.65 $73,256 - $100,984	-1,114 Reduced 6.66%	15,603 $1.03 Million
Q2 2021 Aug 13, 2021	SELL	$57.98 - $96.6 $23,597 - $39,316	-407 Reduced 2.38%	16,717 $1.39 Million
Q1 2021 May 14, 2021	SELL	$71.56 - $121.23 $5,009 - $8,486	-70 Reduced 0.41%	17,124 $1.31 Million
Q4 2020 Feb 08, 2021	SELL	$47.41 - $115.03 $159,013 - $385,810	-3,354 Reduced 16.32%	17,194 $1.52 Million
Q3 2020 Nov 12, 2020	SELL	$43.0 - $84.01 $62,436 - $121,982	-1,452 Reduced 6.6%	20,548 $1.52 Million
Q2 2020 Jul 17, 2020	BUY	$51.3 - $75.21 $1.13 Million - $1.65 Million	22,000 New	22,000 $1.61 Million

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $214M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.